Anti-CD22 [hL22 (Epratuzumab)]

Absolute Antibody

Anti-CD22 [hL22 (Epratuzumab)]

7

This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.

Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).

Flow Cytometry, ImmunoPrecipitation, Neutralisation/Blocking

Blocking; IP; FC

Research Use Only

Monoclonal

hL22 (Epratuzumab)

CD22

CD22 molecule

B-cell receptor CD22; BL-CAM; B-lymphocyte cell adhesion molecule; CD22 antigen; sialic acid-binding Ig-like lectin 2; SIGLEC2; SIGLEC-2; T-cell surface antigen Leu-14

Human

IgG1

B-cell receptor CD22

Human, Monkey, Primate

Human, Rhesus Monkey, Cynomolgus Monkey

This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5–10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).

-20°C,2°C to 8°C

12352203